evo视讯生物

Be the most trusted biotech company

2025-04-09

First Subject Dosed for a Phase 1b/2 Clinical Trial of Henlius’ PD-L1-Targeting ADC HLX43 in Combination with Novel Anti-PD-1 mAb Serplulimab
2025-04-09

The Henlius 2025 Global R&D Day is about to kick off
2025-04-09

Primary Endpoint Met in Phase 3 Clinical Study of Henlius Bevacizumab for Treatment of Ophthalmic Diseases
2025-04-01

Henlius to Present Three Preclinical Studies at AACR 2025
2025-03-28

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
2025-03-27

Latest RWS Results of Serplulimab for SCLC Released at 2025 ELCC
2025-03-26

First Japanese Patient Dosed in Phase 3 MRCT of Dual HER2 Blockade Therapy for HER2+ GC
2025-03-25

Henlius Announces China’s NMPA Approval of Phase 2 Clinical Trial for HLX79 Plus HANLIKANG in Active Glomerulonephritis
2025-03-24

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY